Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure

The goal of phase Ib study was to evaluate efficacy and tolerability of the combination of vebreltinib and furmonertinib in patients with locally advanced or metastatic non-small cell lung cancer with c-met amplification after failure of EGFR-TKI treatment; to determine the maximum tolerated dose (MTD), and to evaluate the dose-limiting toxicity (DLT) and (recommended Phase 2 dose) RP2D of vebreltinib with furmonertinib. The goal of phase II study was to evaluate efficacy \[overall response rate (ORR), progression-free survival (PFS), and so on\] of vebreltinib and furmonertinib in patients w

Trial Details

NCT ID
NCT07087223
Phase
PHASE1 / PHASE2
Sponsor
Peking University Cancer Hospital & Institute
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Vebreltinib combined with Furmonertinib
Locations (sample)
  • Neimeng, Neimeng, China|28.53675,119.33442
  • Neimeng, Neimeng, China|28.53675,119.33442
  • Baoding, China|38.87288,115.46246
  • Baotou, China|40.6516,109.84389
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • Fully aware this study and voluntary to sign the informed consent form, and willing and able to comply with the study procedure.
  • Aged ≥18 years, male or female.
  • Patients with histologically or cytologically confirmed unresectable and non-suitable for radical surgery, or concurrent chemoradiotherapy , locall…
  • Documented EGFR sensitive mutations (exon 19 deletion or exon 21 L858R mutation).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →